SS Innovations (SSII) announced that the company has received regulatory approval for the SSi Mantra surgical robotic system, for multiple indications in Colombia, Oman, Sri Lanka and Kenya. The company received regulatory approval for the SSi Mantra from the Instituto Nacional de Vigilancia de Medicamentos y Alimentos in Colombia in November 2025, from the Directorate General of Pharmaceutical Affairs and Drug Control in Oman in November 2025, from the National Medicines Regulatory Authority in Sri Lanka in January, and from the Pharmacy and Poisons Board in Kenya in January.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SSII:
- SS Innovations Gains Telesurgery Approvals in Indonesia, Philippines
- SS Innovations announces new approvals for Mantra surgical robotic system
- SS Innovations Reports Strong 2025 Growth, Raises New Capital
- SS Innovations reports Q4 EPS (1c) vs. (1c) last year
- SS Innovations Raises Capital to Fund Global Expansion